SCI Pharmtech, Inc.

TWSE:4119 Stock Report

Market Cap: NT$10.6b

SCI Pharmtech Balance Sheet Health

Financial Health criteria checks 5/6

SCI Pharmtech has a total shareholder equity of NT$5.1B and total debt of NT$1.0B, which brings its debt-to-equity ratio to 20.3%. Its total assets and total liabilities are NT$6.7B and NT$1.6B respectively. SCI Pharmtech's EBIT is NT$160.3M making its interest coverage ratio 1303.3. It has cash and short-term investments of NT$1.0B.

Key information

20.3%

Debt to equity ratio

NT$1.04b

Debt

Interest coverage ratio1303.3x
CashNT$1.03b
EquityNT$5.10b
Total liabilitiesNT$1.59b
Total assetsNT$6.69b

Recent financial health updates

No updates

Recent updates

We Think That There Are More Issues For SCI Pharmtech (TWSE:4119) Than Just Sluggish Earnings

Mar 27
We Think That There Are More Issues For SCI Pharmtech (TWSE:4119) Than Just Sluggish Earnings

Analysts Just Shipped A Captivating Upgrade To Their SCI Pharmtech, Inc. (TPE:4119) Estimates

Apr 07
Analysts Just Shipped A Captivating Upgrade To Their SCI Pharmtech, Inc. (TPE:4119) Estimates

There May Be Reason For Hope In SCI Pharmtech's (TPE:4119) Disappointing Earnings

Mar 30
There May Be Reason For Hope In SCI Pharmtech's (TPE:4119) Disappointing Earnings

SCI Pharmtech, Inc. (TPE:4119) Is Yielding 6.3% - But Is It A Buy?

Mar 08
SCI Pharmtech, Inc. (TPE:4119) Is Yielding 6.3% - But Is It A Buy?

SCI Pharmtech (TPE:4119) Shareholders Booked A 54% Gain In The Last Three Years

Jan 25
SCI Pharmtech (TPE:4119) Shareholders Booked A 54% Gain In The Last Three Years

Some SCI Pharmtech, Inc. (TPE:4119) Analysts Just Made A Major Cut To Next Year's Estimates

Dec 30
Some SCI Pharmtech, Inc. (TPE:4119) Analysts Just Made A Major Cut To Next Year's Estimates

Declining Stock and Solid Fundamentals: Is The Market Wrong About SCI Pharmtech, Inc. (TPE:4119)?

Dec 29
Declining Stock and Solid Fundamentals: Is The Market Wrong About SCI Pharmtech, Inc. (TPE:4119)?

Would SCI Pharmtech, Inc. (TPE:4119) Be Valuable To Income Investors?

Dec 08
Would SCI Pharmtech, Inc. (TPE:4119) Be Valuable To Income Investors?

A Look At The Intrinsic Value Of SCI Pharmtech, Inc. (TPE:4119)

Nov 17
A Look At The Intrinsic Value Of SCI Pharmtech, Inc. (TPE:4119)

Financial Position Analysis

Short Term Liabilities: 4119's short term assets (NT$2.0B) exceed its short term liabilities (NT$569.9M).

Long Term Liabilities: 4119's short term assets (NT$2.0B) exceed its long term liabilities (NT$1.0B).

Debt to Equity History and Analysis

Debt Level: 4119's net debt to equity ratio (0.1%) is considered satisfactory.

Reducing Debt: 4119's debt to equity ratio has increased from 0% to 20.3% over the past 5 years.

Debt Coverage: 4119's debt is well covered by operating cash flow (20.8%).

Interest Coverage: 4119's interest payments on its debt are well covered by EBIT (1303.3x coverage).

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.